PhRMA’s Molly Jenkins on 340B program: 'without any evidence that patients benefit'
Molly Jenkins of PhRMA said increased scrutiny of the federal 340B drug pricing program highlights concerns about rising costs without clear patient benefits. Read More »
Alerts Sign-up